InterMune (NASDAQ:ITMN)

Bull and Bear

Top Analyst Upgrades and Downgrades: Enphase, Goldman Sachs, InterMune, Melco Crown, SunEdison and More

Stocks were firm on Tuesday after the S&P 500 hit 2,000 for the first time this week. Investors remain opportunistic for value and individual overlooked stocks. 24/7 Wall St. reviews ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Foot Locker, CBOE, InterMune, US Steel and More

Stocks were firm on Monday, with Dow futures above 17,000 and with the S&P 500 futures up at almost 1,995. Investors have been focused on growth and value on a ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: HP, InterMune, MeetMe, Tesla and More

Stocks were firm on Thursday, another indication that stocks are rising on thin trading volume. Investors have still be repositioning themselves and have been nibbling on stocks when they see ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Cisco, Exxon, Ford, GM, InterMune, Tesla, Twitter and More

Stocks were very strong on Thursday morning. Investors have been using the recent weakness and volatility to accumulate some stocks they may have previously missed. 24/7 Wall St. reviews dozens ...
Read Full Story »
biotech

The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher

Over the years biotech investors who have owned the right stocks have made some very big money on Federal Drug Administration (FDA) approval of leading drug candidates. Typically biotech firms ...
Read Full Story »
Biotechnology word cloud

After Idenix: The Next Four Biotech Buyout Candidates

Wall Street likes nothing better than to start the week off with a bang, and pharmaceutical giant Merck & Co. Inc. (NYSE: MRK) rang the bell Monday by spending $3.85 ...
Read Full Story »
Biotechnology word cloud

Stifel Says Strong Earnings Will Reignite Biotech Rally

When the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering and intense selling knocked a quick 17% off the index ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: AMD, Apple, CDW, Facebook, J.C. Penney and More

Stocks are challenging new highs regularly now, but investors are nervous not to buy the top or to avoid the next major market sell off. 24/7 Wall St. looks over ...
Read Full Story »
Stock Split Image

Five Huge Sell Ratings After News: Tesla, InterMune and More

The higher the market goes, the more likely analysts are to pull the trigger on names they think are stretched. The problem for analysts: In a hot market, stocks often ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Deckers, InterMune, Medivation, Pan American Silver and More

Stocks are hitting news high, earnings season is winding down and Washington, D.C., seems to no longer be a concern. Investors still worry about buying the top and about the ...
Read Full Story »
stock symbol ticker

The 4 Stocks That Dominated the Market on Tuesday

February 25, 2014: Markets opened slightly higher on Tuesday then bounced around the break-even line right up until the closing bell. Consumer goods, materials, and services tried to keep momentum ...
Read Full Story »
research

InterMune Lung Treatment Brings Buyout Gains, Without a Buyout

Shares of biotech company InterMune Inc. (NASDAQ: ITMN) more than doubled Tuesday after the company said its experimental drug pirfenidone, in a late-stage trial, reduced the progression of a disease ...
Read Full Story »
research

J.P. Morgan: Two Biotech Stocks to Buy With 65% to 100% Upside

Most of the major mega cap biotechnology companies have reported earnings and the results almost across the board have been very good. The problem for many investors is many of ...
Read Full Story »
Pills

Teva Acquisition Machine Gears Up: Who Is the Next Target?

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares recently hit a 52-week high after the chief financial officer of the maker of generic medicines said at a conference the company intends ...
Read Full Story »
Pills

UBS Has Nine Biotech Buyout and Merger Candidates

After three years of solid outperformance, most firms on Wall Street that we cover remain very positive on biotechnology as a whole. The analysts at UBS are not only bullish ...
Read Full Story »